Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 3Warts 1Vaginal Diseases 1Uterine Cervical Neoplasms 1Recurrence 1Pneumonia, Pneumococcal 1Pneumococcal Infections 1Papillomavirus Infections 1Neoplasms 1Multiple Myeloma 1Immunologic Deficiency Syndromes 1Hematologic Neoplasms 1Glioma 1Febrile Neutropenia 1Esophageal Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Condylomata Acuminata 1Cervical Cancer Screening 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Ipilimumab 17tremelimumab 9Nivolumab 9durvalumab 8pembrolizumab 6Paclitaxel 5Carboplatin 4Capecitabine 4Bevacizumab 4lenvatinib 3spartalizumab 2balstilimab 2Radiotherapy 2Radiation 2Pemetrexed 2Oxaliplatin 2Doxorubicin 2Docetaxel 2Cisplatin 2CTLA-4 Antigen 2Blood Specimen Collection 2trastuzumab deruxtecan 1tilsotolimod 1tebentafusp 1relatlimab 1poly ICLC 1osimertinib 1folfirinox 1eribulin 1envafolimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diabetes Mellitus, Insulin-Dependent, 12 × Vaccination × Clear all
NCT01216436 2015-05-25

Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma

Duke University

Phase 1 Terminated
2 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡